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Early Vaccinations Are Not Risk Factors for
Celiac Disease
WHAT’S KNOWN ON THIS SUBJECT: Celiac disease is an
immunologic disorder with autoimmune features. Sweden
experienced an epidemic of celiac disease in infants (1984–1996).
Early vaccinations might inﬂuence the risk for autoimmune
diseases, and could potentially have contributed to celiac disease
risk and the epidemic.
WHAT THIS STUDY ADDS: Early vaccinations within the national
Swedish program are not risk factors for celiac disease, nor do
changes over time contribute to explaining the Swedish epidemic.
A protective effect by vaccination against tuberculosis (bacillus
Calmette-Guérin) is suggested.
abstract
OBJECTIVES: To investigate if changes in the national Swedish vacci-
nation program coincided with changes in the celiac disease (CD) in-
cidence rate in infants (ie, the Swedish CD Epidemic), and to assess the
potential association between these vaccinations and CD risk.
METHODS: All studies were based on the National Swedish Childhood
Celiac Disease Register. Using an ecological approach, we plotted
changes over time in the national vaccination program in the graph dis-
playing CD incidence rate. A population-based incident case-referent
study of invited infants was performed. Exposure information was
received through a questionnaire and child health clinic records.
Vaccines explored were diphtheria/tetanus, pertussis (acellular), polio
(inactivated), Haemophilus inﬂuenzae type b (conjugated), measles/
mumps/rubella, and live attenuated bacillus Calmette-Guérin (BCG) in
children with increased tuberculosis risk. Findings were subjected to
a birth cohort analysis.
RESULTS: Introduction of pertussis vaccine coincided in time with de-
creasing CD incidence rates. In the infant case-referent study,
however, neither vaccination against pertussis (odds ratio 0.91; 95%
conﬁdence interval 0.60–1.4), nor against Haemophilus inﬂuenzae type
b or measles/mumps/rubella was associated with CD. Coverage for the
diphtheria/tetanus and polio vaccines was 99%. BCG was associated with
reduced risk for CD (adjusted odds ratio 0.54; 95% conﬁdence interval
0.31–0.94). Discontinuation of general BCG vaccination did not affect the
cumulative incidence of CD at age 15 years.
CONCLUSIONS: Early vaccinations within the national Swedish pro-
gram were not associated with CD risk, nor could changes in the pro-
gram explain the Swedish epidemic. A protective effect by BCG was
suggested, which could be subject to further studies. Pediatrics
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ARTICLE
Celiac disease (CD) is an immunologic
disorder with autoimmune features1
affecting approximately 0.5% to 2.0% of
the general population,2,3 and is more
common in girls than boys.4 In infants,
the disease predominantly presentswith
gastrointestinal symptoms,5 whereas in
children and adults the clinical spectrum
varies from vague to severe symptoms.6
Prerequisites for disease development
are genetic predisposition (human
leukocyte antigen [HLA]-DQ2 or HLA-DQ8)
and exposure to wheat gluten proteins
and related prolamines in rye and barley.
In individuals developing CD, ingestion
of these prolamines causes a small
intestinal lesion characterized by villous
atrophy, crypt hyperplasia, and pro-
duction of interferon-g by T cells.1,7,8
Production of antibodies to wheat glu-
ten and autoantigens, such as tissue-
transglutaminase, is characteristic. On
a gluten-free diet, interferon-g and an-
tibody production ceases and the small
intestinal lesion resolves.2
From 1984 to 1996, Sweden experienced
an epidemic of symptomatic CD among
infants.9,10 The epidemic pattern, a rapid
fourfold increase in incidence rate, fol-
lowed by an equally abrupt decline 1
decade later, is unique for an immuno-
logic and autoimmune disease, indica-
ting that not only genetics but also
environmental and lifestyle factors have
a causal role in disease development.
Probable contributing factors should
have affected a large proportion of the
pediatric population, changed over time,
and had the potential to affect the im-
mune system. The cause of the epidemic
has partly been attributed to changes in
infant feeding practices,11 but among
additional contributing factors, 1 possi-
ble candidate is early vaccinations.
Most countries worldwide have a na-
tional vaccination program for chil-
dren. In Sweden, the ﬁrst national
program was initiated in the 1940s and
today encompasses 9 vaccines for
routine use and another 4 areoffered to
risk groups.12 Since initiation of the
ﬁrst program, changes have been made
regarding types of vaccines used, age at
administration, and number of doses.13
Because vaccinesmodulate the immune
system, they have been proposed to be
causal risk or protective factors for
autoimmune diseases14–16 (eg, type 1
diabetes [T1D]). Because CD has auto-
immune traits and shares several fea-
tures with T1D, this may also apply to
CD.17 To our knowledge, the potential
association between CD and vaccinations
has not been previously analyzed. We
hypothesized that immunologic respon-
ses to vaccinations may inﬂuence the
immune reaction toward gluten proteins
and thereby affect the risk for CD in ge-
netically predisposed individuals.
The objectives of this study were two-
fold: to investigate if changes in the
national Swedish vaccination program
coincided with the changes in CD in-
cidence rate in the beginning and endof
the Swedish CD epidemic, and to assess
the potential association between early
vaccinations and CD risk.
METHODS
Study Design
Different epidemiologic designs were
used (Fig 1). The National Swedish
Childhood Celiac Disease Register, with
quality-controlled data for the period
from 1973 to 2003, constituted the basis
for all studies. To investigate if changes
in the national Swedish vaccination
program coincided in time with changes
seen in CD incidence rate, an ecological
approach was used. To assess the po-
tential association between early vacci-
nations and CD risk, we used an incident
case-referent design. Relevant ﬁndings
from the infant case-referent study were
compared between birth cohorts.
National Swedish Childhood Celiac
Disease Register
The incidence register was initiated in
1991 with 14 pediatric clinics, covering
40% of the pediatric population, pro-
spectively reporting all new cases. In
1998, the register becamenationwide.9,10
For the period 1973 to 1991, 5 units,
covering 15% of the pediatric popula-
tion, reported retrospectively (Fig 1).
Included cases were younger than 15
years of age and had biopsy-veriﬁed CD,
according to criteria set by the European
Society of Pediatric Gastroenterology,
Hepatology, and Nutrition.18 Popula-
tion data were obtained from Statistics
Sweden (www.scb.se).
Ecological Approach
The ecological approach focused on
changes in the vaccination program
starting 4 years before until 4 years
after the increase and decrease, re-
spectively, in CD incidence rate. In the
graph displaying the incidence rate in
infants, we plotted the point in time
when new or modiﬁed vaccines were
introduced and any changes over time
in vaccination population coverage.
Data on changes in the national vacci-
nationprogramwere obtained from the
Swedish Council on Technology As-
sessment in Health Care13 and data on
vaccination coverage in children at 2
years of age were obtained from the
Swedish Institute for Infectious Disease
Control (www.smittskyddsinstitutet.se)
and the National Board of Health and
Welfare (www.socialstyrelsen.se).
Infant Case-Referent Study
From November 1, 1992, to April 30,
1995, all children reported to the CD
register (n = 714) were invited to
a case-referent study called “Child
Health in the 1990s” (Fig 2). Require-
ments for participation were informed
consent with full personal identity
number, and biopsy-veriﬁed CD accord-
ing to European Society of Pediatric
Gastroenterology, Hepatology, and Nu-
trition.18 During this period, 3 consecu-
tive small intestinal biopsies constituted
the established routine in Sweden for
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diagnosis in infants (ie, a ﬁrst biopsy for
diagnosis followed by a second during
a gluten-free diet, and a third after glu-
ten challenge).19 This routine for di-
agnosis was required for participation,
excluding 38 children. Of the eligible
children, 475 were infants at diagnosis
and included in this study (Fig 2). For
every case, 2 referents were selected
from the national population register
after matching for date of birth, gender,
and residence area. All cases and ref-
erents received a questionnaire re-
garding family characteristics, infant
feeding, and the child’s general health.
The questionnaire did not reveal the
special interest in CD. For prospectively
recorded data on early vaccinations, we
requested the child health clinic re-
cords from well-baby clinics, with data
on type of vaccinations given and date of
administration. Both the questionnaire
and the child health clinic record were
available for 428 cases and 693 refer-
ents. Inclusion criteria were deﬁned as
a matched set of 1 case with 1 or 2
referents with complete information on
all vaccinations. The ﬁnal analyses in-
cluded 1015 infants: 392 cases (83%) and
623 referents (66%) (Fig 2).
Comparison Between Birth Cohorts
Based on the register data, the cumula-
tive incidenceofCDat15yearsofagewas
compared for different birth cohorts to
further analyze relevant ﬁndings in the
infantcase-referentstudy. Informationon
vaccinationswasobtainedfromthesame
sources as for the ecological approach.
Vaccines
Vaccinationswithin the national Swedish
program were explored; thus, the study
was restricted to vaccines in routine use.
The program, at the time of interest,
included diphtheria/tetanus toxoid vac-
cine (DT), acellular pertussis vaccine
(Pa), inactivated polio vaccine (IPV), con-
jugated Haemophilus inﬂuenzae type
b vaccine (Hib), attenuated measles/
mumps/rubella vaccine (MMR), and
for children in risk groups, also vacci-
nation against tuberculosis with live
attenuated variant of Mycobacterium
bovis (ie, bacillus Calmette-Guérin
vaccine [BCG]).13 Further details are
given in Table 1.
Deﬁnitions
Infant was deﬁned as a child younger
than 2 years. The infant’s vaccination
status was deﬁned as vaccinated for
a given vaccine after the date the initial
dose was given, and unvaccinated until
then. Infants with CD were considered
unvaccinated, with respect to their dis-
ease, if vaccinated after diagnosis. Age
at CD diagnosis was deﬁned as age at
the ﬁrst small intestinal biopsy, and
the referents in each matched set re-
ceived the same cutoff age. As previo-
usly described in detail,11 breastfeeding
included both exclusive and partial
breastfeeding. Breastfeeding at the time
of gluten introduction was catego-
rized into discontinued the month be-
fore introduction, continued the month
during introduction, and continued be-
yond that time. The amount of gluten-
containing ﬂour per day, 2 weeks after
introduction, was calculated from ques-
tionnaire data and standard recipes.11
Statistical Analyses
The CD incidence ratewas calculated as
the number of new cases divided by the
total person-time at risk, approximated
as the midyear population each year.
Vaccination coveragewas presented as
percentages of vaccinated infants per
birth cohort, and once with mean value
with SD. Cumulative incidence of CD per
birth cohort was calculated as the total
numberof cases per yeardivided by the
number of children in that population
FIGURE 1
Epidemiologic studies based on the Swedish National Childhood Celiac Disease Register (CD register)
with coverage (%) of the pediatric population. The dotted line represents retrospectively collected data
and the solid line represents prospectively collected data. At indicated time periods, an ecological
approach, a case-referent study, and comparison between cohorts were performed.
FIGURE 2
Flow chart depicting number of participants in
the infant CD case-referent study. Numbers of
children and percentages are given in the boxes.
Boxes with dotted lines indicate excluded chil-
dren. Gray shaded areas indicate invited infants
and those included in the ﬁnal analysis.
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birth cohort. A difference in cumulative
incidence of CD between birth cohorts
was evaluatedby using thex2 test. In the
infant case-referent study, variables
were presented by using proportions
and, when appropriate, median values
with interquartile range. Missing ans-
wers for possible confounders were
coded as separate categories. Associa-
tions between categorical variableswere
compared for cases and referents, with
x2 tests and stratiﬁed analyses per-
formed, including stratiﬁcations for
gender. Conditional logistic regression
models were developed and evaluated in
bivariate andmultivariate analyses. Data
summarization and statistical analyses
were done with PASW Statistics 18 (SPSS
Inc, Chicago, IL). Statistical signiﬁcance
was deﬁned as P, .05 or an odds ratio
(OR) with a 95% conﬁdence interval (CI)
not including 1.0.
Ethical Considerations
The research ethics committees of all
Swedish medical faculties and the
SwedishData InspectionBoardapproved
the study. All participating families gave
informed consent.
RESULTS
Ecological Approach to Celiac
Disease and Vaccinations
The incidence rate of CD in infants
changed in a pattern resembling an
epidemic between 1984 and 1996, and
during that period the national vaccina-
tion program underwent some changes
(Fig 3). Vaccination with DT and IPV
remained unchanged, with coverage of
∼99%. In the early 1980s, BCG vaccina-
tion coverage increased but remained
largely the same during the epidemic
period (mean 13.8%6 1.2% SD).
In 1982, 2 years before the increase in CD
incidence rate, MMR combination vac-
cine replaced the separate vaccines for
measles and rubella, and at the same
time, a vaccine against mumps was in-
troduced.Thischangeoccurredtooearly
to explain the increase in CD incidence
rate. Hib was introduced in 1992, which
was in themiddleof theepidemicperiod.
In 1996, after years of large clinical tri-
als,13 Pa was introduced. The clinical
trials and subsequent introduction of Pa
coincided in time with the decrease in
CD incidence rate (Fig 3).
Characteristics of the Study
Subjects in the Infant
Case-Referent Study
The study population consisted of 392
infantswithCD,whereof two-thirdswere
girls,and theirgender-andage-matched
referents (n = 623) (Fig 2). Median age
at onset of symptoms indicative of CD
was 11 months (interquartile range 9–
13 months). Median age at diagnosis
was 15 months (interquartile range 12–
17 months).
Vaccination Against Pertussis (Pa)
and CD Risk
From the ecological approach, intro-
duction of Pa could be connected in
time to the decrease in CD incidence
rate. In 1996, Pa reached almost com-
plete coverage; however, because the
infant case-referent study was per-
formed during the years of the clinical
trials, ∼25% of the infants were vacci-
nated (Table 2). In the infant case-
referent study, we found no association
between Pa and CD risk (OR 0.91; 95% CI
0.6–1.4). Vaccination coverage and sep-
arate risk assessments were similar for
boys and girls (data not shown).
Vaccination With DT, IPV, Hib and
MMR, and CD Risk
We found that both cases and referents
received DT, IPV, Hib, and MMR to ap-
proximately the same extent (Table 2).
Risk assessment in relation to DT and
IPV was not feasible owing to 99% vac-
cination coverage. CD risk was not asso-
ciated with Hib, or with MMR. Vaccination
coverage and separate risk assessments
were similar for boys and girls (data not
shown).
Vaccination Against Tuberculosis
(BCG) and CD Risk
In the infant case-referent study, 4.8%of
the CD cases were BCG vaccinated and
the corresponding number for the
referents was 8.5% (Table 3). Median
age for BCG vaccination was 5.3 months
among cases and 0.2 months for refer-
ents (P = .02). Girls received BCG more
often than boys (9.3% vs 4.1%, P = .003).
The decreased risk for CD among
TABLE 1 Vaccinations Within the National Swedish Vaccination Program During the Epidemic Period
Disease Vaccinea Type of Vaccine Age at First Dose, mo Route Combinationsb
Diphtheria D Inactivated toxin 3 IM DT: DTPa during trial and after Pa introduction
Tetanus T Inactivated toxin 3 IM
Pertussis Pa Acellular component 3 IM
Polio IPV Inactivated virus 3 IM IPV: IPV+Hib after introduction
Haemophilus inﬂuenzae type b Hib Conjugated component 3 IM
Measles M Attenuated virus 18 SC MMR
Mumps M Attenuated virus 18 SC
Rubella R Attenuated virus 18 SC
Tuberculosis BCG Live attenuated 0 or 6 ID
ID, intradermal; IM, intramuscular; SC, subcutanous.
a Abbreviation for vaccine name.
b Main combinations are presented. They differed depending on time (Fig 3) and geographical area.
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infants vaccinated with BCG remained
signiﬁcant in the multivariate analysis
(adjusted OR 0.54; 95% CI 0.31–0.94),
even after adjusting for 2 exposures
suggested to affect CD risk (Table 3).
Separate assessments showed ad-
justed OR 0.54 (95% CI 0.29–0.99) for
girls, and adjusted OR 0.48 (95% CI
0.11–2.07) for boys. As in our previous
reports,11 there was a reduced risk for
CD in infants who were breastfed at and
beyond introduction of gluten-containing
ﬂour and an increased risk for CD in
infants receiving large amounts of ﬂour
(Table 3). ORs suggested that BCG vac-
cination was at least as efﬁcient as
breastfeeding in decreasing the risk for
CD (Table 3).
BCG and Comparison Between
Birth Cohorts
General vaccination against tubercu-
losis with BCG was replaced with a se-
lective strategy in 1975. This caused
a drop in vaccination coverage from
∼95% before 1975 to∼2% in 1976/77.20
The selective strategy involved vac-
cination of risk groups: (1) children
potentially exposed to persons with
tuberculosis; (2) children whose parents
came from countries with a high occur-
rence of tuberculosis; and (3) children
in families planning to stay for longer
periods in an area where tuberculosis is
common.12,21 This was reﬂected in the
characteristics of the BCG-vaccinated
group, most commonly with 1 or 2
parents from a country other than
Sweden, for both cases and referents.
The change in strategy in 1975 enabled
a comparison between different birth
cohorts. Children born in 1973/74 had
the same cumulative incidence of CD
at 15 years of age as children born in
1976/77 (P = .47) (Fig 4).
DISCUSSION
In this study, by using different epide-
miologic designs, we found no associ-
ation between early vaccinations and
risk for CD. On the contrary, a protec-
tive effect by BCG vaccination was sug-
gested.Neitherchangesover time in the
national Swedish vaccination program,
nor changes in the population’s vaccina-
tion coverage contributed to explaining
the changes in CD incidence rate (ie, the
Swedish CD epidemic).
Vaccinations have long been discussed
as potential protective or risk fac-
tors for autoimmune diseases. The hy-
pothesis has been that vaccinations,
particularly live attenuated vaccines,
such as BCG,15 affect the risk through
1 or more of the following mechanisms:
(1) molecular mimicry; (2) impact on
the developing immune system (eg,
regulatory T cells); or (3) nonspeciﬁc
immunologic effects (eg, heterolo-
gous immunity).15,16,22 These mecha-
nisms are partly the same as proposed
for how infections and microbiota
might affect the risk for autoimmune
diseases.16,23,24
FIGURE 3
Changes over time in CD incidence rate in infants10 in relation to changes over time in the national
Swedish vaccination program, including both introductions of new vaccines and changes in vacci-
nation coverage at 2 years of age. The diamond shape indicates the year when the respective vaccine
was introduced into the program.
TABLE 2 Vaccination Coverage for Cases and Referents and Association with CD
Exposuresa Descriptives Bivariate Logistic
Regressionb
Cases (n = 392) n (%) Referents (n = 623) n (%) OR (95% CI)
Pertussis (Pa)
Nonvaccinated 291 (74) 457 (73) 1.0
Vaccinated 101 (26) 166 (27) 0.91 (0.60–1.37)
Haemophilus inﬂuenzae type b (Hib)
Nonvaccinated 81 (21) 132 (21) 1.0
Vaccinated 311 (79) 491 (79) 1.01 (0.68–1.52)
Measles/mumps/rubella (MMR)
Nonvaccinated 320 (82) 512 (82) 1.0
Vaccinated 72 (18) 111 (18) 0.99 (0.58–1.69)
a Vaccines within the national Swedish program.
b Conditional logistic regression using matched sets of case and referent(s).
ARTICLE
PEDIATRICS Volume 130, Number 1, July 2012 e67
Toourknowledge, therearenoprevious
studies on vaccinations and CD risk. As
CD and T1D share several features, we
turned to experiences from diabetes
research. Although contradictory results
have been presented,25,26 a large Euro-
pean multicenter study on T1D found no
association with early vaccinations.27 In
our study, we found no association be-
tween Pa, Hib, orMMRand CD risk, which
agrees with ﬁndings in T1D.
Regarding BCG, most studies that
have shown nonspeciﬁc effects were
performed in low-income countries
or investigated the relationship with
asthma.28,29 Albeit conﬂicting results,
studies have shown effects that can-
not be attributed to the protection of
tuberculosis and a stronger effect for
girls compared with boys.29–32 On the
contrary, previous studies on BCG and
T1D found no association,27,33 but the
evidence remains inconsistent.34 In our
study, BCG vaccination was signiﬁcant-
ly associated with decreased risk for
CD (adjusted OR 0.54), but with no dif-
ference between girls and boys. Ref-
erents received BCG at a younger age,
which could indicate that to exert
a protective effect, BCG has to be given
early in life. Conversely, in the birth co-
hort comparison, we found no signiﬁ-
cant difference in cumulative incidence
of CD at 15 years of age, and comparable
results for T1Dwere shown in Sweden.35
Since 1975, Sweden has a selective
BCG vaccination strategy. Therefore,
the BCG-vaccinated group constitutes
a risk group for tuberculosis and,
consequently, the assumption of ex-
changeability is compromised. A re-
cent Swedish study showed a lower
incidence of CD in second-generation
immigrants from low-prevalence coun-
tries, indicating genetic effects, but could
not exclude involvement of environmen-
tal factors36 (eg, intestinalmicrobiota37,38).
This is in accordance with our results,
because such a strong association be-
tween BCG and CD risk (OR = 0.54)
probably could not be attributed only to
differences in genetics. Overall, a pro-
tective effect by BCG was suggested, but
the association should be interpreted
with caution.
A strength of this study is that it is
based on the quality-controlled National
Swedish Childhood Celiac Disease Reg-
ister. The register encompasses the vast
majority of all cases, because all sus-
pected cases are referred to a pediatric
unit for diagnosis. At each unit, a contact
person reports all incident cases to the
registerandmostcasesarereportedwith
full personal identity number,39 enabling
follow-up. In the infant case-referent
study, referents were randomly selected
from the national population register,
after matching criteria were fulﬁlled, and
invited at the same time as the case.
Referents could consequently be consid-
ered representative. The vaccination data
TABLE 3 Vaccination Against Tuberculosis (BCG) and Association With CD, Including Adjustment
for Other Exposures Suggested to Affect CD Risk
Exposuresa Descriptives Bivariate Logistic
Regressionb
Multivariate Logistic
Regressionc
Cases
(n = 392)
n (%)
Referents
(n = 623)
n (%)
OR (95% CI) OR (95% CI)
BCG vaccination
Nonvaccinated 373 (95) 570 (92) 1.0 1.0
Vaccinated 19 (4.8) 53 (8.5) 0.54 (0.32–0.93) 0.54 (0.31–0.94)
Breastfeeding at
introduction of ﬂour
Discontinued 196 (50) 179 (29) 1.0 1.0
Continued 89 (23) 136 (22) 0.59 (0.42–0.84) 0.62 (0.43–0.88)
Continued beyond 82 (21) 242 (39) 0.33 (0.24–0.46) 0.37 (0.26–0.52)
Nonresponsed 25 (6.4) 66 (11) 0.37 (0.22–0.61) 0.56 (0.24–1.27)
Amount of ﬂour per day 2
weeks after the ﬁrst
portion
Small-Medium 184 (47) 344 (55) 1.0 1.0
Large 174 (44) 189 (30) 1.86 (1.38–2.51) 1.45 (1.05–1.99)
Nonresponsed 34 (8.7) 90 (14) 0.75 (0.49–1.16) 0.80 (0.39–1.63)
a BCG and infant feeding practices. For deﬁnitions, see Methods.
b Conditional logistic regression using 392 matched sets of case and referent(s).
c Multivariate model including both BCG and infant feeding.
d The questionnaire was not completely answered.
FIGURE 4
Cumulative incidence of CD in birth cohorts before and after a changed strategy for BCG vaccination. In
1975, general BCGwasreplacedwith aselective strategy. Subsequently, BCGcoveragedropped from95%
in 1973/74 to 2% in 1976/77. The CD cumulative incidence at 15 years of age remained unchanged.
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were well deﬁned, prospectively recor-
ded in the well-baby clinic, and therefore
robust. In the national vaccination pro-
gram, however, MMR is administrated at
18 months of age (Table 1), which could
be too late to affect CD risk, as most
children had not received the MMR
before CD diagnosis (median age 15
months). Questionnaire data on pos-
sible confounders have been evalu-
ated \by using “imputation missing
value analysis” without signiﬁcant im-
pact on results.11 Some questions had
nonresponses, but this did not affect the
outcome. The cohort analysis was based
on the CD register for the period 1973 to
1991, which covered 15%of the pediatric
population (Fig 1). At that time, CD was
relatively uncommon, which resulted in
few cases, yielding a low power for this
analysis. In this study, we used different
epidemiologic designs; however, in the
event of inconsistency between results,
the case-referent design provides the
best evidence, as it uses data on the in-
dividual level.
Oneof the consequences of the epidemic
wasshownbyscreeningchildrenborn in
1993 at 12 years of age, revealing a CD
prevalence of 3%.4 This remarkably high
prevalence emphasizes the need to un-
derstandwhat caused the epidemic. The
current study excludes 1 possible can-
didate factor.
CONCLUSIONS
Early vaccinations within the national
Swedish program were not associated
with CD risk. The Swedish epidemic of
CD is not fully understood, and changes
in the vaccination program or coverage
do not contribute to the explanation. We
found no epidemiologic evidence that
the immunologic response to vaccina-
tions increases CD risk. Interestingly,
a protective effect by BCG is suggested;
however, the BCG-vaccinated group con-
stitutes a risk group for tuberculosis and
therefore the result should be inter-
preted with caution until conﬁrmed in
further studies.
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